AQST Aquestive Therapeutics, Inc.
Legal ·
Modica v. Aquestive names the company and chief executive Daniel Barber in New Jersey federal court. A derivative suit, Wilson v. Brown, is stayed behind it.
The facility refinances Aquestive's existing debt. It starts with $55.0 million at signing and adds tranches tied to FDA approval and sales milestones.
Aquestive sold 21,250,000 shares at $4.00 through Leerink Partners, Cantor and Oppenheimer, a day after agreeing to a conditional $75 million revenue-interest deal with an affiliate of RTW Investments. Anaphylm's approval is a condition of that deal.
Aquestive Therapeutics is a pharmaceutical company developing medicines that deliver complex molecules through alternatives to invasive and inconvenient standard of care therapies. Its late-stage product candidate, Anaphylm (dibutepinephrine), is a sublingual film for severe allergic reactions, including anaphylaxis, which the company describes as the first and only non-device based, orally delivered epinephrine prodrug in development. The FDA issued a complete response letter (CRL) on January 30, 2026, focused on administration and labeling guidance, and Aquestive plans a new human factors validation study and a resubmission of the NDA. Its AdrenaVerse platform contains a library of over twenty epinephrine prodrug product candidates, including AQST-108, an epinephrine topical gel. Its PharmFilm oral film technology has been used to ship more than two billion doses to patients worldwide. Aquestive also has four licensed commercialized products that its licensees market, and it is the exclusive manufacturer of those products.
| Product or program | What it is | Stage |
|---|---|---|
| Anaphylm (dibutepinephrine) sublingual film | Oral epinephrine prodrug film for severe allergic reactions including anaphylaxis | CRL received January 30, 2026; NDA resubmission planned |
| AQST-108 (epinephrine) topical gel | Epinephrine prodrug candidate from the AdrenaVerse platform | |
| PharmFilm | Oral film drug delivery technology |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $17.2 million | $20.3 million |
| Net income (loss) | -$83.8 million | -$44.1 million |
| Cash from operations | -$52.4 million | -$35.8 million |
| Cash and equivalents | $121.2 million | $71.5 million |
Our latest story on this, dated Sep 17, 2026: "Aquestive faces securities class action and derivative suit over Anaphylm NDA statements". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2025: "Aquestive Therapeutics prices $85,000,000 stock offering at $4.00 per share". The story links the filing or release it is based on. Read the story.
Aquestive Therapeutics, Inc. trades under the ticker AQST on NASDAQ.
Aquestive Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Aquestive Therapeutics, Inc. is 1398733. Its filings are on SEC EDGAR.
125,511,648 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Aquestive Therapeutics, Inc. under United States.
Our directory classifies Aquestive Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aquestive Therapeutics, Inc. is US03843E1047.
aibio.space lists Aquestive Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Aquestive Therapeutics is a pharmaceutical company developing medicines that deliver complex molecules through alternatives to invasive and inconvenient standard of care therapies. Its late-stage product candidate, Anaphylm (dibutepinephrine), is a sublingual film for severe allergic reactions, including anaphylaxis, which the company describes as the first and only non-device based, orally delivered epinephrine prodrug in development.
Anaphylm (dibutepinephrine) sublingual film: Oral epinephrine prodrug film for severe allergic reactions including anaphylaxis Stage: CRL received January 30, 2026; NDA resubmission planned.
AQST-108 (epinephrine) topical gel: Epinephrine prodrug candidate from the AdrenaVerse platform
Aquestive Therapeutics, Inc. reported a net loss of $83.8 million for the fiscal year ended Dec 31, 2025, and used $52.4 million of cash in operations, per its annual report to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.02,2.03,3.02,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio